Civitas’ Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant
This article was originally published in The Pink Sheet Daily
Executive Summary
Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.
You may also be interested in...
Disease Foundations Are Finding Their Way In New Research Relationships
Disease foundations have realized that funding basic research is not enough to serve their patient groups, but forging those later-stage relationships can be tricky and all parties involved are developing new flexibilities, panelists at the BIO annual meeting said June 21 in Boston.
As Pharma Looks Beyond The Molecule For Innovation, Can VCs Take Advantage?
Big Pharma’s growing interest in innovation beyond the molecule that improves health outcomes could provide new opportunities for biotechs and their venture capital backers, but in many areas investors have approached cautiously.
Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.